Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449754 | 0.88 | NPSR1 (0.57) | CTNNB1WNT3ANPSR1CES2ALDH1A1 | |
| SCHEMBL8384471 | 0.86 | CTNNB1 (0.54) | CTNNB1WNT3ANPSR1CES2ALDH1A1 | |
| SCHEMBL19707220 | 0.84 | NPSR1 (0.56) | CTNNB1WNT3ANPSR1CES2ALDH1A1 | |
| SCHEMBL3032732 | 0.83 | CTNNB1 (0.60) | CTNNB1WNT3ANPSR1CES2ALDH1A1 | |
| SCHEMBL15988788 | 0.82 | CTNNB1 (0.67) | CTNNB1WNT3ACES2ALDH1A1POLB | |
| SCHEMBL9468405 | 0.81 | ALDH1A1 (0.61) | CTNNB1WNT3ANPSR1CES2ALDH1A1 | |
| SCHEMBL744906 | 0.81 | CTNNB1 (0.62) | CTNNB1WNT3ACES2ALDH1A1POLB | |
| SCHEMBL30758861 | 0.81 | CES2 (0.69) | CTNNB1WNT3ANPSR1CES2ALDH1A1 | |
| SCHEMBL1274789 | 0.81 | NPSR1 (0.50) | CTNNB1WNT3ANPSR1CES2ALDH1A1 | |
| SCHEMBL9745666 | 0.80 | CES2 (0.59) | CTNNB1WNT3ANPSR1CES2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606255-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2098508-A1 | Cyclic derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| EP-1606255-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1606255-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071460-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | CTNNB1 4537/4885WNT3A 2895/4885NPSR1 309/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | CTNNB1 4310/4885WNT3A 2739/4885NPSR1 304/4885 |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CTNNB1 4537/4885WNT3A 2895/4885NPSR1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.